Thioredoxin Systems AB is a growing organisation, supported by an expert advisory board, dedicated to the development of EbsArgent® as a new solution to antimicrobial resistance.
A world-renowned scientist in redox biology and biotechnological applications with more than 170 publications and four granted patents, who succeeded Prof. Arne Holmgren as head of the Division of Biochemistry at MBB, Karolinska Institutet. Elias has effectively translated his successful academic research into commercial ventures within biotechnology and medicine, bridging scientific ingenuity with real-world impact. Through astute leadership and exceptional business intelligence he has promoted fast-paced technology development and efficient market entry of several companies, fostering innovation.
email@example.com | +46 72-322 22 21
A seasoned business visionary who holds executive positions at rapidly growing global companies operating in the medical device and pharmaceutical markets. Mohamad has an extensive scientific background which he has leveraged to build innovation and transform scientific discoveries into commercial products. With an extensive track record as a board member, he adeptly navigates complex market regulations and provides strategic guidance to ventures focused on pioneering technologies.
Carlos Ratia Loncán, PhD
A clinical microbiologist with a PhD from the University of Barcelona where his primary research focused on novel antibiotics targeting multidrug-resistant pathogens. Carlos has also specifically explored metalloantibiotics as inhibitors of the bacterial thioredoxin system. His expertise encompasses resistance mechanisms and antibacterial efficacy across various conditions, coupled with comprehensive experience in designing and analysing in-vivo studies.
Business Developer & Administrator
A business developer with a degree in financing from Lund University School of Economics and Management. Isak has diverse and valuable experience from working in several early-stage innovative ventures, bringing his expertise in business administration to support their growth and success. He believes in the power of start-ups and SMEs to drive innovation and societal beneficial change.
Mikael Thomsen, PhD
An expert drug developer with more than 25 years’ experience from the pharmaceutical industry. Mikael has a PhD in pharmacology & toxicology and has worked at Novartis Pharma, Novo Nordisk and various European biotech companies where he held roles such as Chief Development Officer, CSO and Head of R&D. He also co-founded several biotech companies himself and has worked for the U.S. Food and Drug Administration (FDA).
Helen Steel, MD
A pharmaceutical industry expert with extensive experience in infectious diseases R&D. Was a Director of Clinical Development at GlaxoSmithKline for 15 years, and later became the Head Unit Physician for the Infectious Diseases Therapeutic Area. Helen has led a global team of pharmacovigilance professionals in her position as Head of Shared Safety Sciences and has nearly 30 years’ experience in the pharmaceutical development industry.